DK2289518T3 - Terapeutisk middel mod inflammatoriske tarmsygdomme - Google Patents
Terapeutisk middel mod inflammatoriske tarmsygdomme Download PDFInfo
- Publication number
- DK2289518T3 DK2289518T3 DK09770108.0T DK09770108T DK2289518T3 DK 2289518 T3 DK2289518 T3 DK 2289518T3 DK 09770108 T DK09770108 T DK 09770108T DK 2289518 T3 DK2289518 T3 DK 2289518T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- acid
- inflammatory bowel
- bowel diseases
- agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (2)
1. 2-{4-[N-5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}eddiksyre eller 2-{4-[N-5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamid, eller et farmaceutisk acceptabelt salt deraf, til anvendelse ved behandling af inflammatoriske tarmsygdomme.
2. Forbindelse til anvendelse ifølge krav 1, hvor den inflammatoriske tarmsygdom er Colitis ulcerosa, Morbus Crohn, intestinal tuberkulose, iskæmisk colitis eller intestinal ulcer i tilknytning til Behcet sygdom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008162640 | 2008-06-23 | ||
| PCT/JP2009/061287 WO2009157398A1 (ja) | 2008-06-23 | 2009-06-22 | 炎症性腸疾患治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2289518T3 true DK2289518T3 (da) | 2017-01-16 |
Family
ID=41444464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09770108.0T DK2289518T3 (da) | 2008-06-23 | 2009-06-22 | Terapeutisk middel mod inflammatoriske tarmsygdomme |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8394793B2 (da) |
| EP (1) | EP2289518B1 (da) |
| JP (1) | JP5527206B2 (da) |
| KR (1) | KR101639821B1 (da) |
| CN (1) | CN102065864B (da) |
| CA (1) | CA2728161C (da) |
| CY (1) | CY1118390T1 (da) |
| DK (1) | DK2289518T3 (da) |
| ES (1) | ES2611483T3 (da) |
| HR (1) | HRP20170030T1 (da) |
| HU (1) | HUE032108T2 (da) |
| LT (1) | LT2289518T (da) |
| PL (1) | PL2289518T3 (da) |
| PT (1) | PT2289518T (da) |
| SI (1) | SI2289518T1 (da) |
| WO (1) | WO2009157398A1 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102705198B1 (ko) | 2009-06-26 | 2024-09-11 | 니뽄 신야쿠 가부시키가이샤 | 결정 |
| WO2011024874A1 (ja) * | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | 塩基付加塩 |
| CN104586853A (zh) * | 2014-12-31 | 2015-05-06 | 武汉联程生物科技有限公司 | 一种用于治疗外伤性颅脑创伤的药物组合物及其制备方法 |
| AU2016366073B2 (en) * | 2015-12-02 | 2021-08-26 | Nippon Shinyaku Co., Ltd. | Pharmaceutical composition containing 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N- (methylsulfonyl)acetamide |
| CN109563055B (zh) * | 2016-07-29 | 2021-12-24 | 成都苑东生物制药股份有限公司 | 氨基吡嗪类化合物或盐、异构体、其制备方法及用途 |
| JOP20190204A1 (ar) | 2017-03-08 | 2019-09-05 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على سيليكسيباغ |
| TWI801421B (zh) | 2017-09-28 | 2023-05-11 | 日商日本新藥股份有限公司 | 結晶 |
| BR112020008940A2 (pt) | 2017-11-16 | 2020-10-20 | Nippon Shinyaku Co., Ltd. | preparação de liberação controlada |
| JP2021512902A (ja) | 2018-02-07 | 2021-05-20 | メッドシャイン ディスカバリー インコーポレイテッド | プロスタサイクリン受容体アゴニスト |
| CA3154802A1 (en) | 2019-10-23 | 2021-04-29 | Marc Patrik SCHRADER | Pharmaceutical composition comprising selexipag |
| WO2021152060A1 (en) | 2020-01-31 | 2021-08-05 | Actelion Pharmaceuticals Ltd | Controlled release selexipag composition |
| TW202241425A (zh) | 2021-01-29 | 2022-11-01 | 瑞士商艾克泰聯製藥有限公司 | 用於製造二苯基吡𠯤衍生物之程序 |
| TW202239408A (zh) | 2021-01-29 | 2022-10-16 | 瑞士商艾克泰聯製藥有限公司 | 包含二苯基吡𠯤衍生物的醫藥組成物 |
| WO2023131608A1 (en) | 2022-01-04 | 2023-07-13 | Actelion Pharmaceuticals Ltd | Controlled release compositions |
| WO2023214059A1 (en) | 2022-05-06 | 2023-11-09 | Actelion Pharmaceuticals Ltd | Diphenylpyrazine compounds as prodrugs |
| WO2024017964A1 (en) | 2022-07-20 | 2024-01-25 | Actelion Pharmaceuticals Ltd | Injectable pharmaceutical composition comprising a diphenylpyrazine derivative |
| WO2024133620A1 (en) | 2022-12-22 | 2024-06-27 | Actelion Pharmaceuticals Ltd | In vitro dissolution test |
| WO2024194449A1 (en) | 2023-03-23 | 2024-09-26 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition comprising a diphenylpyrazine derivative |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO440696A0 (en) * | 1996-12-30 | 1997-01-23 | Fujisawa Pharmaceutical Co., Ltd. | New use |
| TWI316055B (da) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| US7326716B2 (en) * | 2003-06-06 | 2008-02-05 | Allergan, Inc. | Treatment of inflammatory bowel disease |
| US7101906B2 (en) * | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| DK2246336T3 (da) * | 2008-02-28 | 2020-07-20 | Nippon Shinyaku Co Ltd | Fibroseinhibitor |
-
2009
- 2009-06-22 CN CN2009801246843A patent/CN102065864B/zh active Active
- 2009-06-22 ES ES09770108.0T patent/ES2611483T3/es active Active
- 2009-06-22 WO PCT/JP2009/061287 patent/WO2009157398A1/ja active Application Filing
- 2009-06-22 LT LTEP09770108.0T patent/LT2289518T/lt unknown
- 2009-06-22 DK DK09770108.0T patent/DK2289518T3/da active
- 2009-06-22 HU HUE09770108A patent/HUE032108T2/en unknown
- 2009-06-22 EP EP09770108.0A patent/EP2289518B1/en active Active
- 2009-06-22 CA CA2728161A patent/CA2728161C/en active Active
- 2009-06-22 PT PT97701080T patent/PT2289518T/pt unknown
- 2009-06-22 PL PL09770108T patent/PL2289518T3/pl unknown
- 2009-06-22 SI SI200931585A patent/SI2289518T1/sl unknown
- 2009-06-22 US US13/000,791 patent/US8394793B2/en active Active
- 2009-06-22 KR KR1020107028238A patent/KR101639821B1/ko active IP Right Grant
- 2009-06-22 JP JP2010517993A patent/JP5527206B2/ja active Active
-
2016
- 2016-12-23 CY CY20161101341T patent/CY1118390T1/el unknown
-
2017
- 2017-01-10 HR HRP20170030TT patent/HRP20170030T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2611483T3 (es) | 2017-05-09 |
| LT2289518T (lt) | 2017-01-10 |
| CA2728161C (en) | 2017-06-06 |
| HUE032108T2 (en) | 2017-08-28 |
| CY1118390T1 (el) | 2017-06-28 |
| CA2728161A1 (en) | 2009-12-30 |
| JPWO2009157398A1 (ja) | 2011-12-15 |
| EP2289518A4 (en) | 2012-04-11 |
| EP2289518B1 (en) | 2016-11-02 |
| PT2289518T (pt) | 2016-11-18 |
| HRP20170030T1 (hr) | 2017-03-24 |
| JP5527206B2 (ja) | 2014-06-18 |
| CN102065864B (zh) | 2012-11-21 |
| US8394793B2 (en) | 2013-03-12 |
| KR20110036537A (ko) | 2011-04-07 |
| CN102065864A (zh) | 2011-05-18 |
| US20110118254A1 (en) | 2011-05-19 |
| PL2289518T3 (pl) | 2017-03-31 |
| WO2009157398A1 (ja) | 2009-12-30 |
| SI2289518T1 (sl) | 2017-02-28 |
| KR101639821B1 (ko) | 2016-07-14 |
| EP2289518A1 (en) | 2011-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2289518T3 (da) | Terapeutisk middel mod inflammatoriske tarmsygdomme | |
| EP1257275B1 (fr) | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac | |
| KR101614996B1 (ko) | 증가된 생체이용률을 갖는 커큐민을 포함하는 수용성 조성물 및 이의 방법 | |
| JP5249388B2 (ja) | 糖尿病の治療及び予防のためのフタリド誘導体の使用 | |
| JP2006518751A (ja) | 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物 | |
| JP2008512453A (ja) | 胃酸の急速かつ持続的な抑制のための製剤、オメプラゾール制酸剤複合体−即時放出物 | |
| BR112013025420B1 (pt) | Medicamento, composição farmacêutica, métodos para produzir uma composição farmacêutica e para prevenir ou tratar uma doença, kit, uso de um composto, e de um medicamento, e, medicamento | |
| CN104306363B (zh) | 芪类衍生物及其药学可接受的盐在制备治疗高尿酸血症药物中的应用 | |
| CN110248659A (zh) | 肝病治疗剂 | |
| ES2423929T3 (es) | Composición farmacéutica que contiene suspensión basada en aceite de partículas finas | |
| TWI336254B (en) | Pharmaceutical composition for treating abdominal discomfort | |
| EP1919472B1 (en) | Compositions and methods for treatment and prevention of hyperuricemia related health consequences | |
| EP1853256A2 (en) | Organic compounds | |
| EP2637645B1 (fr) | Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation | |
| JPH05509293A (ja) | 不整脈および発作の治療における５―ｈｔ４受容体拮抗剤の使用 | |
| TW201521786A (zh) | 胺碘酮類似物（ｂｕｄｉｏｄａｒｏｎｅ）調配物 | |
| EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
| RU2690685C2 (ru) | Фармацевтические композиции, содержащие алпелисиб | |
| ES2262322T3 (es) | Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar. | |
| KR0136787B1 (ko) | 심장질환 치료에 쓰이는 프로파페논과 퀴니딘의 지속성 조성물 | |
| US7495024B2 (en) | Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque | |
| US20120029048A1 (en) | Phenylalkyl n-hydroxyureas for treating leukotriene related pathologies | |
| JP4528490B2 (ja) | ギンコライド−ａを含有する抗不安剤 | |
| FR3072567A1 (fr) | Composition pharmaceutique ou dietetique contenant de l’extrait d’origanum majorana et utilisable pour reguler le cycle enterosystemique intestinal de l’eau. | |
| Azad et al. | Recent Advances in Delivering Strategies of Domperidone: Challenges and Opportunities |